A Small Cytotoxic Peptide from Frog Elicits Potent Antitumor Immunity to Prevent Local Tumor Growth and Metastases

References

• Von Hoff DD , ErvinT, ArenaFPet al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med.369(18), 1691–1703 (2013).
   PubMed Web of Science ®Google Scholar
• Malhotra V , PerryMC. Classical chemotherapy: mechanisms, toxicities and the therapeutic window. Cancer Biol. Ther.2(4 Suppl. 1), S2–S4 (2003).
   PubMed Web of Science ®Google Scholar
• Thundimadathil J . Cancer treatment using peptides: current therapies and future prospects. J. Amino. Acids2012, 967347 (2012).
   PubMedGoogle Scholar
• Mitchell EP . Gastrointestinal toxicity of chemotherapeutic agents. Semin. Oncol.33(1), 106–120 (2006).
   PubMed Web of Science ®Google Scholar
• Goldman B . Multidrug resistance: can new drugs help chemotherapy score against cancer?J. Natl Cancer Inst.95(4), 255–257 (2003).
   PubMedGoogle Scholar
• Luqmani YA . Mechanisms of drug resistance in cancer chemotherapy. Med. Prin. Pract.14(Suppl. 1), 35–48 (2005).
   PubMed Web of Science ®Google Scholar
• Kyi C , PostowMA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS. Lett.588(2), 368–376 (2014).
   PubMed Web of Science ®Google Scholar
• Intlekofer AM , ThompsonCB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J. Leukocyte Biol.94(1), 25–39 (2013).
   PubMed Web of Science ®Google Scholar
• Callahan MK , WolchokJD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J. Leukocyte Biol.94(1), 41–53 (2013).
   PubMed Web of Science ®Google Scholar
• Michallet M , MaloiselF, DelainMet al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a Phase III study. Leukemia18(2), 309–315 (2004).
   PubMed Web of Science ®Google Scholar
• Pachella LA , MadsenLT, DainsJE. The toxicity and benefit of various dosing strategies for interleukin-2 in metastatic melanoma and renal cell carcinoma. J. Adv. Pract. Oncol.6(3), 212–221 (2015).
   PubMedGoogle Scholar
• Robert C , ThomasL, BondarenkoIet al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med.364(26), 2517–2526 (2011).
   PubMed Web of Science ®Google Scholar
• Prieto PA , YangJC, SherryRMet al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin. Cancer Res.18(7), 2039–2047 (2012).
   PubMed Web of Science ®Google Scholar
• Galluzzi L , SenovillaL, ZitvogelL, KroemerG. The secret ally: immunostimulation by anticancer drugs. Nat. Rev. Drug. Discov.11(3), 215–233 (2012).
   PubMed Web of Science ®Google Scholar
• Zitvogel L , KeppO, KroemerG. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol.8(3), 151–160 (2011).
   PubMed Web of Science ®Google Scholar
• Vincent J , MignotG, ChalminFet al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res.70(8), 3052–3061 (2010).
   PubMed Web of Science ®Google Scholar
• Vanneman M , DranoffG. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer12(4), 237–251 (2012).
   PubMed Web of Science ®Google Scholar
• Bracci L , SchiavoniG, SistiguA, BelardelliF. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell. Death Differ.21(1), 15–25 (2014).
   PubMed Web of Science ®Google Scholar
• Vacchelli E , PradaN, KeppO, GalluzziL. Current trends of anticancer immunochemotherapy. Oncoimmunology2(6), e25396 (2013).
   PubMed Web of Science ®Google Scholar
• Spranger S , KoblishHK, HortonB, ScherlePA, NewtonR, GajewskiTF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J. Immunother. Cancer2, 3 (2014).
   PubMedGoogle Scholar
• Curran MA , MontalvoW, YagitaH, AllisonJP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA107(9), 4275–4280 (2010).
   PubMed Web of Science ®Google Scholar
• Chen Y , XiaR, HuangYet al. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat. Commun.7, 13443 (2016).
   PubMed Web of Science ®Google Scholar
• Hemshekhar M , AnapartiV, MookherjeeN. Functions of cationic host defense peptides in immunity. Pharmaceuticals9(3), 1–10 (2016).
   Google Scholar
• Mansour SC , PenaOM, HancockRE. Host defense peptides: front-line immunomodulators. Trends Immunol.35(9), 443–450 (2014).
   PubMed Web of Science ®Google Scholar
• Ren SX , ChengAS, ToKFet al. Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer. Cancer Res.72(24), 6512–6523 (2012).
   PubMed Web of Science ®Google Scholar
• Papo N , ShaiY. Host defense peptides as new weapons in cancer treatment. Cell. Mol. Life. Sci.62(7–8), 784–790 (2005).
   PubMed Web of Science ®Google Scholar
• Furlong SJ , MaderJS, HoskinDW. Bovine lactoferricin induces caspase-independent apoptosis in human B-lymphoma cells and extends the survival of immune-deficient mice bearing B-lymphoma xenografts. Exp. Mol. Pathol.88(3), 371–375 (2010).
   PubMed Web of Science ®Google Scholar
• Hancock RE , NijnikA, PhilpottDJ. Modulating immunity as a therapy for bacterial infections. Nat. Rev. Microbiol.10(4), 243–254 (2012).
   PubMed Web of Science ®Google Scholar
• Hancock RE , SahlHG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol.24(12), 1551–1557 (2006).
   PubMed Web of Science ®Google Scholar
• Roudi R , SynNL, RoudbaryM. Antimicrobial peptides as biologic and immunotherapeutic agents against cancer: a comprehensive overview. Front. Immunol.8, 1320 (2017).
   PubMed Web of Science ®Google Scholar
• Scott MG , DullaghanE, MookherjeeNet al. An anti-infective peptide that selectively modulates the innate immune response. Nat. Biotechnol.25(4), 465–472 (2007).
   PubMed Web of Science ®Google Scholar
• Liu YY , HanTY, GiulianoAE, HansenN, CabotMC. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J. Biol. Chem.275(10), 7138–7143 (2000).
   PubMed Web of Science ®Google Scholar
• Kurokawa M , KornbluthS. Caspases and kinases in a death grip. Cell138(5), 838–854 (2009).
   PubMed Web of Science ®Google Scholar
• Hu W , GeY, OjciusDMet al. p53 signalling controls cell cycle arrest and caspase-independent apoptosis in macrophages infected with pathogenic Leptospira species. Cell. Microbiol.15(10), 1642–1659 (2013).
   PubMed Web of Science ®Google Scholar
• Soengas MS , LoweSW. Apoptosis and melanoma chemoresistance. Oncogene22(20), 3138–3151 (2003).
   PubMed Web of Science ®Google Scholar
• Kook SH , SonYO, ChungSWet al. Caspase-independent death of human osteosarcoma cells by flavonoids is driven by p53-mediated mitochondrial stress and nuclear translocation of AIF and endonuclease G. Apoptosis12(7), 1289–1298 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang Y , ChenF. Reactive oxygen species (ROS), troublemakers between nuclear factor-κB (NF-κB) and c-Jun NH2-terminal kinase (JNK). Cancer Res.64(6), 1902–1905 (2004).
   PubMed Web of Science ®Google Scholar
• Pearson G , RobinsonF, BeersGibson Tet al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev.22(2), 153–183 (2001).
   PubMed Web of Science ®Google Scholar
• Al-Azayzih A , GaoF, GocA, SomanathPR. TGFbeta1 induces apoptosis in invasive prostate cancer and bladder cancer cells via Akt-independent, p38 MAPK and JNK/SAPK-mediated activation of caspases. Biochem. Biophys. Res. Commun.427(1), 165–170 (2012).
   PubMed Web of Science ®Google Scholar
• Park D-H , XuHD, ShimJet al. Stephania delavayi Diels. inhibits breast carcinoma proliferation through the p38 MAPK/NF-κB/COX-2 pathway. Oncol. Rep.26(4), 833–841 (2011).
   PubMed Web of Science ®Google Scholar
• Heuvers ME , AertsJG, CornelissenR, GroenH, HoogstedenHC, HegmansJP. Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer12(1), 580 (2012).
   PubMedGoogle Scholar
• Zhang Y , LiN, SuhH, IrvineDJ. Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity. Nat. Commun.9(1), 6 (2018).
   PubMedGoogle Scholar
• van Horssen R , TenHagen TL, EggermontAM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist11(4), 397–408 (2006).
   PubMed Web of Science ®Google Scholar
• Ni J , MillerM, StojanovicA, GarbiN, CerwenkaA. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J. Exp. Med.209(13), 2351–2365 (2012).
   PubMed Web of Science ®Google Scholar
• Bellmann-Weiler R , SchrollA, EnglSet al. Neutrophil gelatinase-associated lipocalin and interleukin-10 regulate intramacrophage Chlamydia pneumoniae replication by modulating intracellular iron homeostasis. Immunobiology218(7), 969–978 (2013).
   PubMed Web of Science ®Google Scholar
• Iida N , NakamotoY, BabaTet al. Tumor cell apoptosis induces tumor-specific immunity in a CC chemokine receptor 1- and 5-dependent manner in mice. J. Leukoc. Biol.84(4), 1001–1010 (2008).
   PubMed Web of Science ®Google Scholar
• Vendramini-Costa DB , de CarvalhoJE. Molecular link mechanisms between inflammation and cancer. Curr. Pharm. Des.18(26), 3831–3852 (2012).
   PubMed Web of Science ®Google Scholar
• Lee HS , ParkCB, KimJMet al. Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide. Cancer Lett.271(1), 47–55 (2008).
   PubMed Web of Science ®Google Scholar
• Huang TC , LeeJF, ChenJY. Pardaxin, an antimicrobial peptide, triggers caspase-dependent and ROS-mediated apoptosis in HT-1080 cells. Mar. drugs9(10), 1995–2009 (2011).
   PubMed Web of Science ®Google Scholar
• Park IJ , KimMJ, ParkOJet al. Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and MAPK regulation. Cancer Lett.298(1), 88–98 (2010).
   PubMed Web of Science ®Google Scholar
• Pulaski BA , TermanDS, KhanS, MullerE, Ostrand-RosenbergS. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res.60(10), 2710–2715 (2000).
   PubMed Web of Science ®Google Scholar